Ampio Pharmaceuticals June 15th Short Interest Update

Ampio Pharmaceuticals (NYSEMKT:AMPE) reported a rise of 1.7% or 126,760 shares in its short interest. The short figure came in at 15.6% of the total floats. The average daily volume of 309,413 shares suggests that the days to cover 7,689,956 short positions, as on June 15,2016, will be 25. On May 31,2016, the short interest was 7,563,196 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

Ampio Pharmaceuticals (NYSEMKT:AMPE): The stock opened at $3.20 on Friday but the bulls could not build on the opening and the stock topped out at $3.34 for the day. The stock traded down to $3.20 during the day, due to lack of any buying support eventually closed down at $3.30 with a loss of -1.20% for the day. The stock had closed at $3.34 on the previous day. The total traded volume was 4,172,735 shares.

The company shares have rallied 32.00% from its 1 Year high price. On May 3, 2016, the shares registered one year high at $4.32 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $3.73 and the 200 Day Moving Average price is recorded at $3.02.

Stocks of Ampio Pharmaceuticals (NYSEMKT:AMPE) rallied by 2.48% during the past week but lost 12.47% on a 4-week basis. The company has outperformed the S&P 500 by 4.19% in the past week but underperformed the index by 9.82% in the last 4 weeks.

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions. The Companys two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. The Company is also focused on developing and monetizing its Oxidation Reduction Potential (ORP) diagnostic device and sexual dysfunction portfolio. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA) for the treatment of osteoarthritis and other inflammatory conditions. Optina is a low-dose formulation of danazol for the treatment of diabetic macular edema (DME). The Companys subsidiaries include Luoxis Diagnostics, Inc. (Luoxis), an in-vitro diagnostics company, and Vyrix Pharmaceuticals, Inc. (Vyrix), a specialty pharmaceutical company.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.